Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01765569
Registration number
NCT01765569
Ethics application status
Date submitted
9/01/2013
Date registered
10/01/2013
Date last updated
23/09/2015
Titles & IDs
Public title
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Query!
Scientific title
A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Query!
Secondary ID [1]
0
0
2012-003459-13
Query!
Secondary ID [2]
0
0
GO28394
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malignant Melanoma, Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Digoxin
Treatment: Drugs - Vemurafenib
Experimental: Vemurafenib + Digoxin - Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
Treatment: Drugs: Digoxin
Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
Treatment: Drugs: Vemurafenib
Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUClast) of Digoxin
Query!
Assessment method [1]
0
0
AUClast = Area under the plasma-concentration time curve from time zero to the last measurable plasma concentration which is presented in hour*nanogram per milliliter (hour*ng/mL). Hour 0 (H0) signified pre-dose sampling.
Query!
Timepoint [1]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [2]
0
0
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Digoxin
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [3]
0
0
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) of Digoxin
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [4]
0
0
Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC168) of Digoxin
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [5]
0
0
Maximum Plasma Concentration (Cmax) of Digoxin
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [6]
0
0
Time to Maximum Plasma Concentration (Tmax) of Digoxin
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [7]
0
0
Terminal Half-Life (t1/2) of Digoxin
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Primary outcome [8]
0
0
Apparent Clearance (CL/F) of Digoxin
Query!
Assessment method [8]
0
0
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Query!
Timepoint [8]
0
0
Hour [H] 0, 0.5, 1, 2, 3, 4, 6, 8, 10-12 (Day [D] 1), 24, 30-32 (D2), 48 (D3), 72 (D4), 96 (D5), 168 (D8) post-digoxin dose; H0, 0.5, 1, 2, 3, 4, 6, 8, and 10-12H (D29), 24, 30-32 (D30), 48 (D31), 72 (D32), 96 (D33), 168 (D36) post digoxin dose
Query!
Eligibility
Key inclusion criteria
- Male or female patients >= 18 years old
- Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive
for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating
mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a
DNA sequencing method, and who have no acceptable standard treatment options
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Life expectancy >= 12 weeks
- Full recovery from the effects of any major surgery or significant traumatic injury
within 14 days prior to the first dose of study treatment
- Adequate hematologic and end organ function
- Female patients of childbearing potential and male patients with partners of
childbearing potential must agree to always use two effective methods of contraception
- Negative serum pregnancy test within 7 days prior to commencement of dosing in women
of childbearing potential
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose
of study drug
- Prior anti-cancer therapy within 28 days before the first dose of study drug
- History of clinically significant cardiac or pulmonary dysfunction
- History of symptomatic congestive heart failure of any New York Heart Association
class or serious cardiac arrhythmia requiring treatment
- History of myocardial infarction within 6 months prior to first dose of study drug
- Current dyspnea at rest, owing to complications of advanced malignancy or any
requirement for supplemental oxygen to perform activities of daily living
- History of congenital long QT syndrome or QTc > 450 ms
- Current digoxin therapy or anticipated requirement to take digoxin therapy during the
study
- Active central nervous system lesions
- Uncontrolled or poorly controlled diabetes
- Current severe, uncontrolled systemic disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
29
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Belarus
Query!
State/province [1]
0
0
Minsk District
Query!
Country [2]
0
0
Belarus
Query!
State/province [2]
0
0
Minsk
Query!
Country [3]
0
0
Belarus
Query!
State/province [3]
0
0
Vitebsk
Query!
Country [4]
0
0
Israel
Query!
State/province [4]
0
0
Haifa
Query!
Country [5]
0
0
Israel
Query!
State/province [5]
0
0
Tel Aviv
Query!
Country [6]
0
0
Israel
Query!
State/province [6]
0
0
Tel Hashomer
Query!
Country [7]
0
0
Korea, Republic of
Query!
State/province [7]
0
0
Daegu
Query!
Country [8]
0
0
Korea, Republic of
Query!
State/province [8]
0
0
Seoul
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
Kazan
Query!
Country [10]
0
0
Russian Federation
Query!
State/province [10]
0
0
Moscow
Query!
Country [11]
0
0
Russian Federation
Query!
State/province [11]
0
0
St. Petersburg
Query!
Country [12]
0
0
South Africa
Query!
State/province [12]
0
0
Johannesburg
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This open-label, multi-center, three-period, one sequence study will investigate the effect
of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable
BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a
V600-activating mutation of BRAF without acceptable standard treatment options. Patients will
receive multiple doses of vemurafenib in Periods B and C and a single dose of digoxin in
Periods A and C. Eligible patients will have the option to continue treatment with
vemurafenib as part of an extension study (NCT01739764). The anticipated time on study
treatment is approximately 36 days.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01765569
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01765569
Download to PDF